Santarus Announces Development Program For New ZEGERID Prescription Product

Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, announced that it is developing a new tablet formulation to add to its ZEGERID family of branded prescription pharmaceutical products. The new formulation is a swallowable tablet that combines immediate-release omeprazole, a proton pump inhibitor (PPI), with a mix of buffers. Santarus plans to undertake clinical and stability studies with the tablet in preparation for the submission of a New Drug Application to the U.S.

Added: 21 июня 2008

Last relative articles:

Comments: [0] / Post comment:

06 Jan 2009 08:00:59

Depomeds License Agreement With Solvay Pharmaceuticals Clears HSR ... - Earthtimes (press release)

Depomeds License Agreement With Solvay Pharmaceuticals Clears HSR ... Earthtimes (press release), UK - GLUMETZA (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus , Inc. in the ...

Source: http://news.google.com/news/url

05 Jan 2009 16:06:14

Depomed Announces Management Promotions - Reuters

Depomed Announces Management Promotions Reuters - GLUMETZA (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus , Inc. in the United ...

Source: http://reuters.com/article/pressRelease/idUS106889+05-Jan-20~

02 Jan 2009 20:27:04

$8.2M Industrial Park Opening in Otay Mesa - San Diego Business Journal

$8.2M Industrial Park Opening in Otay Mesa San Diego Business Journal, CA - Bilbro Construction has completed Class A tenant improvements for Santarus , a specialty pharmaceutical company, at 3811 Valley Center Drive in Del Mar ...

Source: http://sdbj.com/industry_article.asp

20 Dec 2008 05:48:01

Santarus Collaborates with Cosmo for US Rights to Budesonide MMX ... - Trading Markets (press release)

Santarus Collaborates with Cosmo for US Rights to Budesonide MMX ... Trading Markets (press release), CA - According to the company, terms of the agreements include an upfront payment to Cosmo of cash and Santarus common stock, shared development costs, ...

Source: http://tradingmarkets.com/.site/news/Stock%20News/2094871/

16 Dec 2008 16:08:52

Yields on six-month T-bills fall to record low - San Diego Union Tribune

Yields on six-month T-bills fall to record low San Diego Union Tribune, CA - San Diego-based Santarus said it has acquired exclusive rights to develop an oral corticosteroid and an antibiotic to treat mild to moderate ulcerative ...

Source: http://www3.signonsandiego.com/stories/2008/dec/16/1b16bizbr~

15 Dec 2008 21:51:32

NEWS | SAN DIEGO Santarus gains US rights to two drugs - San Diego Daily Transcript (subscription)

NEWS SAN DIEGO Santarus gains US rights to two drugs San Diego Daily Transcript (subscription), CA - San Diego-based Santarus Inc. (Nasdaq: SNTS) has been granted the US rights to Italian drugmaker Cosmo Pharmaceuticals SpAs experimental medicines ...

Source: http://sddt.com/news/article.cfm

15 Dec 2008 18:03:53

Santarus Nabs US Rights for Two Drugs in Cosmo Collaboration - Xconomy

Santarus Nabs US Rights for Two Drugs in Cosmo Collaboration Xconomy, MA - Santarus will pay Cosmo $2.5 million in cash and 6 million shares of Santarus common stock. Cosmo is also eligible for up to $72.5 million in clinical, ... Piper Jaffray Initiates Coverage on Santarus (SNTS) with a Neutral Santarus Announces Strategic Collaboration with Cosmo for US ... Santarus Inc executes strategic collaboration with Cosmo for ... -

Source: http://xconomy.com/san-diego/2008/12/15/santarus-nabs-us-rig~

15 Dec 2008 12:44:53

Glance-REFILE-STOCKS NEWS EUROPE-Deceuninck rebounds after ... - Hemscott

Glance-REFILE-STOCKS NEWS EUROPE-Deceuninck rebounds after ... Hemscott, UK - Vontobel says the upfront cash fee of $2.5 million, 6 million newly issued Santarus shares and additional milestones should have a positive impact on ...

Source: http://hemscott.com/news/static/tfn/item.do

15 Dec 2008 12:16:49

STOCKS NEWS EUROPE-Cosmo gains 5 pct on US licensing deal - Reuters UK

STOCKS NEWS EUROPE-Cosmo gains 5 pct on US licensing deal Reuters UK, UK - S: Quote, Profile, Research) gain 4.6 percent to 11.50 Swiss francs percent after it signs a strategic collaboration with US company Santarus . ...

Source: http://uk.reuters.com/article/hotStocksNews/idUKLF7075022008~

15 Dec 2008 09:03:22

Cosmo: Strategische Koopeartion mit Santarus fьr US-Rechte bei 2 ... - Swissinfo

Cosmo: Strategische Koopeartion mit Santarus fьr US-Rechte bei 2 ... Swissinfo, Switzerland - Gemдss der Vereinbarung erhalte Santarus die exklusiven Rechte zur Entwicklung und Kommerzialisierung zweier Medikamente fьr den US-amerikanischen Markt, ...

Source: http://swissinfo.ch/ger/news/newsticker/Cosmo_Strategische_K~.html

Keywords:

santarus, product santarus, santarus announces, santarus inc, santarus plans, buffers santarus

ALL NEWS TODAY

Santarus Announces Development Program For New ZEGERID Prescription Product

Keywords: